PlainRecalls
FDA Drug Moderate Class II Ongoing

Duloxetine Delayed-Release Capsules, USP, 20 mg, , 500-count bottles, Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922, NDC 51991-746-05.

Reported: May 15, 2024 Initiated: April 29, 2024 #D-0483-2024

Product Description

Duloxetine Delayed-Release Capsules, USP, 20 mg, , 500-count bottles, Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922, NDC 51991-746-05.

Reason for Recall

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

Details

Units Affected
7,188/ 500 count bottles
Distribution
US Nationwide.
Location
Berlin, CT

Frequently Asked Questions

What product was recalled?
Duloxetine Delayed-Release Capsules, USP, 20 mg, , 500-count bottles, Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922, NDC 51991-746-05.. Recalled by Breckenridge Pharmaceutical, Inc. Units affected: 7,188/ 500 count bottles.
Why was this product recalled?
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
Which agency issued this recall?
This recall was issued by the FDA Drug on May 15, 2024. Severity: Moderate. Recall number: D-0483-2024.